vs
Side-by-side financial comparison of MYRIAD GENETICS INC (MYGN) and Anbio Biotechnology (NNNN). Click either name above to swap in a different company.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $209.8M | — | ||
| Q3 25 | $205.7M | — | ||
| Q2 25 | $213.1M | — | ||
| Q1 25 | $195.9M | — | ||
| Q4 24 | $210.6M | — | ||
| Q3 24 | $213.3M | — | ||
| Q2 24 | $211.5M | — | ||
| Q1 24 | $202.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | $-27.4M | — | ||
| Q2 25 | $-330.5M | — | ||
| Q1 25 | $-100.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-22.1M | — | ||
| Q2 24 | $-36.7M | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | 70.0% | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | 71.2% | — | ||
| Q1 25 | 68.5% | — | ||
| Q4 24 | 71.7% | — | ||
| Q3 24 | 70.2% | — | ||
| Q2 24 | 69.6% | — | ||
| Q1 24 | 68.1% | — |
| Q4 25 | -2.7% | — | ||
| Q3 25 | -11.3% | — | ||
| Q2 25 | -154.5% | — | ||
| Q1 25 | -14.8% | — | ||
| Q4 24 | -18.6% | — | ||
| Q3 24 | -9.4% | — | ||
| Q2 24 | -17.3% | — | ||
| Q1 24 | -13.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | -13.3% | — | ||
| Q2 25 | -155.1% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -10.4% | — | ||
| Q2 24 | -17.4% | — | ||
| Q1 24 | -12.9% | — |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.29 | — | ||
| Q2 25 | $-3.57 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.47 | — | ||
| Q3 24 | $-0.24 | — | ||
| Q2 24 | $-0.41 | — | ||
| Q1 24 | $-0.29 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
